A landmark study presented at the American Society of Clinical Oncology’s annual meeting in Chicago reveals that GLP-1 weight-loss drugs—already prescribed to millions for obesity and diabetes—may slash breast cancer risk by up to 30%, while also reducing mortality and metastasis in existing cases. The findings, published June 2 in JCO Oncology Practice, mark a potential paradigm shift in cancer prevention, though researchers caution that observational data cannot prove causation.
Breast cancer, the most common cancer among U.S. women after skin cancer, accounts for an estimated 380,000 cases annually. Obesity—a known risk factor—is linked to 13 types of cancer, including breast, prostate, and colon. Now, three separate analyses of GLP-1 medications (like Ozempic, Wegovy, and Zepbound) suggest these drugs may offer more than weight management: they could become a frontline tool in cancer prevention and treatment.
Three Studies, One Stunning Signal: GLP-1 Drugs and Breast Cancer
The evidence is mounting. A retrospective analysis of over 110,000 women aged 45 to 80—presented by Dr. Elizabeth McDonald, a professor of radiology at the University of Pennsylvania and breast radiologist at Abramson Cancer Center—found that those taking GLP-1 medications were 30% less likely to develop breast cancer compared to non-users. A second study showed that adding GLP-1s to standard breast cancer treatment reduced patient mortality by 30%, while a third analysis across breast, lung, bowel, and liver cancers revealed up to a 50% reduction in disease spread among those on the drugs.
McDonald’s team matched 15,000 GLP-1 users to a control group of 96,000 non-users, accounting for age, race, BMI, breast density, and diabetes status. The results were consistent: GLP-1 users had a 35.1% lower risk of breast cancer diagnosis. “While our study was observational and does not definitively confirm an association,” McDonald said, “it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.”
“GLP-1 medications are intriguing from a cancer research perspective because they weren’t designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we’re eager to study them in this context.”
According to The Guardian, the drugs’ mechanisms may lie in their multifaceted effects. Beyond weight loss, GLP-1s reduce systemic inflammation—a known contributor to tumor growth—and influence metabolic and epigenetic pathways that could inhibit cancer progression. Previous research has shown these drugs cut the risk of 10 of the 13 obesity-associated cancers by 41% compared to bariatric surgery.
Beyond Breast Cancer: GLP-1s and the Broader Cancer Landscape
The implications extend far beyond breast cancer. A May study published in JCO Oncology Practice found that GLP-1 users were less likely to see their obesity-related cancers spread. While the new breast cancer data is the most robust to date, researchers are now exploring whether these drugs could impact other malignancies, including prostate, pancreatic, and colorectal cancers—all of which are linked to obesity and inflammation.
The New York Post highlighted a 2025 mouse study where tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) led to a 20% reduction in body weight and a 30% decrease in breast cancer tumor size. Though animal studies don’t translate directly to humans, they provide a biological rationale for further investigation.
Yet, the data isn’t without limitations. The observational nature of the studies means correlation doesn’t equal causation. The University of Pennsylvania analysis, for instance, didn’t account for genetic risk factors or whether cancers were detected at an advanced stage. Additionally, the study relied on health records from Penn Medicine facilities, leaving open the question of whether results hold for patients treated elsewhere, such as through telehealth or compounding pharmacies.
What Comes Next: Clinical Trials and the Path to Prevention
McDonald and her colleagues are now pushing for robust clinical trials to test GLP-1s as a preventative measure for high-risk women—those with a family history of breast cancer or other known risk factors. “Ultimately, we want to find better options to prevent breast cancer,” McDonald told reporters. “It’s been encouraging to see the survival rates improve over recent decades, and we’d love to see the same gains in prevention.”
The New York Post noted that while the findings are promising, they don’t yet justify widespread off-label use of GLP-1s for cancer prevention. The drugs carry known side effects, including gastrointestinal distress, pancreatitis risk, and—controversially—potential links to thyroid tumors in animal studies. Regulatory agencies like the FDA would need to weigh these risks against the potential benefits before endorsing GLP-1s as a cancer-prevention strategy.
For now, the focus remains on prevention. If GLP-1s are proven effective, they could offer a dual benefit: reducing obesity and lowering cancer risk in one treatment. But experts warn that routine screenings remain critical, as no intervention can prevent cancer entirely.
The Bigger Picture: Why This Matters for Public Health
The potential of GLP-1s in cancer prevention isn’t just about individual health—it’s about reshaping public health strategies. Breast cancer alone accounts for 30% of all new female cancers annually, with over 320,000 cases expected this year. If GLP-1s can reduce incidence by even a fraction of the observed 30%, the impact could be transformative.
Consider the economic and societal costs: cancer treatment in the U.S. exceeds $200 billion annually, with breast cancer alone driving billions in direct and indirect expenses. A preventative tool that could cut cases by 30% would not only save lives but also alleviate strain on healthcare systems. The drugs are already widely prescribed for obesity and diabetes, meaning the infrastructure for distribution and monitoring is largely in place.
Yet, challenges remain. Access to GLP-1 medications is uneven, with cost and insurance coverage acting as barriers for many. The Guardian pointed out that while the drugs are effective, their high price tags (Wegovy costs over $1,300 per month without insurance) could limit their preventative use unless payers recognize their broader health benefits.
What’s Next: The Road Ahead for GLP-1 Research
The next 12 to 24 months will be critical. Researchers are likely to launch large-scale randomized controlled trials (RCTs) to confirm whether GLP-1s can prevent breast cancer in high-risk populations. The USA Today report emphasized that McDonald’s findings should “only increase the possibility there’s a real biological signal,” but definitive answers will require rigorous testing.
In the meantime, oncologists may begin incorporating GLP-1s into treatment regimens for obese or overweight cancer patients, given the emerging evidence of reduced mortality and metastasis. The drugs’ anti-inflammatory and metabolic effects could also make them valuable adjuncts in chemotherapy or immunotherapy protocols.
For patients, the message is clear: GLP-1s are not a cure-all, and their role in cancer prevention is still under investigation. But for those already prescribed these medications for weight management or diabetes, the new data offers a compelling reason to stay on track—both literally and figuratively. As McDonald put it, “The benefits would be transformative for women’s health.” The question now is whether the medical community—and insurers—will act on that promise.
For readers considering GLP-1 medications for weight loss or diabetes management, consult your healthcare provider to discuss potential risks and benefits, including their role in cancer prevention.
